x
Filter:
Filters applied
- New Drug Reviews
- Powell, JasonRemove Powell, Jason filter
- 2018 - 2023Remove 2018 - 2023 filter
New Drug Reviews
2 Results
- NEW DRUG REVIEW
Topical Clascoterone: The First Novel Agent for Acne Vulgaris in 40 Years
Clinical TherapeuticsVol. 43Issue 10p1638–1644Published online: October 2, 2021- Christopher R. Piszczatoski
- Jason Powell
Cited in Scopus: 0Acne vulgaris is a ubiquitous condition in men and women starting in adolescence. It is often persistent and refractory to multiple treatment methods. Although multiple medications may be used on- or off-label for treatment, many adverse effects and risks exist with these treatments, and there has not been an agent with a novel mechanism of action introduced in 40 years. Clascoterone is a recently approved topical acne medication with the first novel mechanism of action since isotretinoin. The purpose of this article was to review the clinical data regarding the safety and efficacy of topical clascoterone for the treatment of acne vulgaris in male and female subjects aged >12 years. - New Drug Review
Bempedoic Acid: A New Tool in the Battle Against Hyperlipidemia
Clinical TherapeuticsVol. 43Issue 2p410–420Published online: December 28, 2020- Jason Powell
- Chris Piszczatoski
Cited in Scopus: 5This article discusses the pharmacology of bempedoic acid, the trials that led to United States Food and Drug Administration (FDA) approval of its use, and the overall safety and efficacy of this therapy in heterozygous familial hypercholesterolemia, established atherosclerotic cardiovascular disease (ASCVD), and hyperlipidemia.
